Hematide: 18-month Hb maintenance

13 April 2008

US drug developer Affymax and Japanese drug major Takeda have reported strong data on their ongoing Phase II trial to assess the long-term safety and tolerability of anemia drug Hematide. Dosed once every four weeks, the agent successfully maintained mean hemoglobin levels between 11g/dL and 12g/dL for up to 18 months in hemodialysis patients who were previously treated with epoetin alfa, noted the firms, adding that Hematide appeared generally well-tolerated.

81 dialysis patients, originally enrolled in an open-label study to evaluate a switch from epoetin alfa to Hematide, were rolled over to the long-term Phase II trial, and then maintained on the agent for the duration of the follow-up study. The patients received intravenous Hematide once every four weeks for approximately 18 months, totaling 18 doses. Dosing was designed to maintain Hb between 10g/dL-12g/dL.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight